162 related articles for article (PubMed ID: 28741244)
1. Efficacy and Safety of Alternate-Day Versus Daily Dosing of Statins: a Systematic Review and Meta-Analysis.
Awad K; Mikhailidis DP; Toth PP; Jones SR; Moriarty P; Lip GYH; Muntner P; Catapano AL; Pencina MJ; Rosenson RS; Rysz J; Banach M;
Cardiovasc Drugs Ther; 2017 Aug; 31(4):419-431. PubMed ID: 28741244
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of alternate-day dosing versus daily dosing of atorvastatin.
Jafari M; Ebrahimi R; Ahmadi-Kashani M; Balian H; Bashir M
J Cardiovasc Pharmacol Ther; 2003 Jun; 8(2):123-6. PubMed ID: 12808485
[TBL] [Abstract][Full Text] [Related]
3. Daily and intermittent rosuvastatin 5 mg therapy in statin intolerant patients: an observational study.
Meek C; Wierzbicki AS; Jewkes C; Twomey PJ; Crook MA; Jones A; Viljoen A
Curr Med Res Opin; 2012 Mar; 28(3):371-8. PubMed ID: 22256801
[TBL] [Abstract][Full Text] [Related]
4. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
Strandberg TE; Feely J; Sigurdsson EL;
Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
[TBL] [Abstract][Full Text] [Related]
5. Pitavastatin for lowering lipids.
Adams SP; Alaeiilkhchi N; Wright JM
Cochrane Database Syst Rev; 2020 Jun; 6(6):CD012735. PubMed ID: 32557581
[TBL] [Abstract][Full Text] [Related]
6. Impact of 10 mg rosuvastatin daily or alternate-day on lipid profile and inflammatory markers.
Li JJ; Yang P; Liu J; Jia YJ; Li ZC; Guo YL; Wu NQ; Tang YD; Jiang LX
Clin Chim Acta; 2012 Jan; 413(1-2):139-42. PubMed ID: 21983163
[TBL] [Abstract][Full Text] [Related]
7. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
8. A systematic review and meta-analysis on the therapeutic equivalence of statins.
Weng TC; Yang YH; Lin SJ; Tai SH
J Clin Pharm Ther; 2010 Apr; 35(2):139-51. PubMed ID: 20456733
[TBL] [Abstract][Full Text] [Related]
9. Rosuvastatin 5 and 10 mg/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies.
Glueck CJ; Aregawi D; Agloria M; Khalil Q; Winiarska M; Munjal J; Gogineni S; Wang P
Clin Ther; 2006 Jun; 28(6):933-42. PubMed ID: 16860175
[TBL] [Abstract][Full Text] [Related]
10. Effects of morning vs evening statin administration on lipid profile: A systematic review and meta-analysis.
Awad K; Serban MC; Penson P; Mikhailidis DP; Toth PP; Jones SR; Rizzo M; Howard G; Lip GYH; Banach M;
J Clin Lipidol; 2017; 11(4):972-985.e9. PubMed ID: 28826569
[TBL] [Abstract][Full Text] [Related]
11. Statins in hypercholesterolaemia: a dose-specific meta-analysis of lipid changes in randomised, double blind trials.
Edwards JE; Moore RA
BMC Fam Pract; 2003 Dec; 4():18. PubMed ID: 14969594
[TBL] [Abstract][Full Text] [Related]
12. Effects of low-dose atorvastatin and rosuvastatin on plasma lipid profiles: a long-term, randomized, open-label study in patients with primary hypercholesterolemia.
Mazza F; Stefanutti C; Di Giacomo S; Vivenzio A; Fraone N; Mazzarella B; Bucci A
Am J Cardiovasc Drugs; 2008; 8(4):265-70. PubMed ID: 18690760
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.
Plans-Rubió P
Am J Cardiovasc Drugs; 2006; 6(3):177-88. PubMed ID: 16780391
[TBL] [Abstract][Full Text] [Related]
14. A PRISMA-compliant systematic review and meta-analysis of randomized controlled trials investigating the effects of statin therapy on plasma lipid concentrations in HIV-infected patients.
Banach M; Dinca M; Ursoniu S; Serban MC; Howard G; Mikhailidis DP; Nicholls S; Lip GYH; Glasser S; Martin SS; Muntner P; Rysz J; Toth PP; Sahebkar A;
Pharmacol Res; 2016 Sep; 111():343-356. PubMed ID: 27350264
[TBL] [Abstract][Full Text] [Related]
15. An economic analysis of the Atorvastatin Comparative Cholesterol Efficacy and Safety Study (ACCESS).
Smith DG; McBurney CR
Pharmacoeconomics; 2003; 21 Suppl 1():13-23. PubMed ID: 12648031
[TBL] [Abstract][Full Text] [Related]
16. Periodic dosing regimens of atorvastatin and rosuvastatin for dyslipidemia: A systematic review and meta-analysis of randomized controlled trials.
Sridharan K; Sivaramakrishnan G
Eur J Intern Med; 2017 Apr; 39():e21-e23. PubMed ID: 28063659
[No Abstract] [Full Text] [Related]
17. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis.
Law MR; Wald NJ; Rudnicka AR
BMJ; 2003 Jun; 326(7404):1423. PubMed ID: 12829554
[TBL] [Abstract][Full Text] [Related]
18. Alternate-day dosing with statins.
Marcus FI; Baumgarten AJ; Fritz WL; Nolan PE
Am J Med; 2013 Feb; 126(2):99-104. PubMed ID: 23331434
[TBL] [Abstract][Full Text] [Related]
19. Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study.
Schuster H; Barter PJ; Stender S; Cheung RC; Bonnet J; Morrell JM; Watkins C; Kallend D; Raza A;
Am Heart J; 2004 Apr; 147(4):705-13. PubMed ID: 15077101
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
